Does Kaiser Permanente Cover Rezdiffra (Resmetirom)?

How Kaiser Permanente Classifies Rezdiffra on Its Formulary

Kaiser Permanente operates as an integrated HMO, which means the health plan, physician group, and pharmacy system function as a single entity. Rezdiffra sits on Kaiser's closed formulary, restricted to internal prescribing pathways rather than open access through any network provider.

What "Closed Formulary" Means for Members

A closed formulary designation at Kaiser differs from a standard specialty-tier listing at plans like Aetna or UnitedHealthcare. Members cannot fill Rezdiffra at an external pharmacy, even with a valid prescription from an outside hepatologist. The prescription must originate from a Kaiser-employed physician, and the dispensing pharmacy must be within Kaiser's integrated system. This creates an additional access barrier compared with open-network insurers.

Specialty Tier Placement and Cost Sharing

When Kaiser does approve Rezdiffra, the drug typically lands on the specialty tier. Depending on the specific Kaiser plan (e.g., Kaiser Permanente Mid-Atlantic vs. Kaiser Permanente Southern California), specialty-tier cost sharing ranges from 20% to 30% coinsurance after deductible. At the $3,500/month list price, that translates to $700 to $1,050 in monthly out-of-pocket costs before hitting the plan's out-of-pocket maximum. Members enrolled in Kaiser's Medicare Advantage plans may see different cost-sharing structures based on their specific Part D formulary 1.

Prior Authorization Requirements at Kaiser Permanente

Kaiser Permanente classifies Rezdiffra prior authorization as "high difficulty," reflecting both clinical gatekeeping and administrative hurdles. The process runs entirely through Kaiser's internal system.

Clinical Criteria for Approval

Based on Kaiser's internal pharmacy protocols and the FDA-approved labeling, members typically must meet several conditions before authorization is granted:

• Confirmed MASH diagnosis with biopsy or validated non-invasive testing (FibroScan, ELF score, or FIB-4 combined with imaging)
• Fibrosis stage F2 or F3, consistent with the MAESTRO-NASH trial population
• Failure or inadequacy of lifestyle interventions, including documented dietary counseling and structured exercise for a minimum of 6 months
• Prescriber credentialing: the ordering physician must be a Kaiser-employed hepatologist or a Kaiser obesity-medicine specialist
• Baseline liver function tests (ALT, AST, bilirubin) and lipid panel within the preceding 90 days

The FDA approved resmetirom in March 2024 based on the MAESTRO-NASH trial (N=966), which demonstrated MASH resolution without worsening fibrosis in 25.9% of patients on the 80 mg dose versus 9.7% on placebo at 52 weeks 2. Kaiser's authorization criteria align closely with the trial's inclusion parameters, meaning members with F0-F1 fibrosis or decompensated cirrhosis (F4) will almost certainly be denied.

Expected Timeline

Kaiser's internal prior authorization review typically takes 5 to 10 business days for standard requests and 24 to 72 hours for urgent or expedited requests. Members should ask their prescribing physician to submit the request as "urgent" if there is clinical evidence of fibrosis progression.

Step Therapy: What Kaiser Requires Before Rezdiffra

Kaiser Permanente almost certainly applies step therapy principles to Rezdiffra, though the plan does not publish a formal step-therapy protocol for this drug specifically. The internal pathway reflects Kaiser's philosophy of exhausting lower-cost, evidence-based interventions first.

Step 1: Lifestyle Modification

Kaiser expects documented participation in its own weight-management or metabolic health programs. A 2023 Cochrane review confirmed that 7-10% body weight loss produces histologic improvement in MASH in approximately 50% of patients 3. Kaiser's internal programs, including registered-dietitian consultations and structured exercise referrals, serve as the first-line intervention.

Step 2: Metabolic Comorbidity Management

Kaiser will expect optimization of diabetes, dyslipidemia, and hypertension before approving Rezdiffra. For members with type 2 diabetes and concurrent MASH, pioglitazone (which showed MASH resolution rates of 47% in the PIVENS trial) or GLP-1 receptor agonists like semaglutide may be required as prior therapeutic attempts 4. Semaglutide 0.4 mg daily demonstrated MASH resolution in 59% of patients in a phase 2 trial published in the New England Journal of Medicine 5.

Step 3: Rezdiffra Authorization

Only after documented failure or intolerance of steps 1 and 2, combined with confirmed fibrosis staging, will Kaiser's pharmacy and therapeutics committee consider Rezdiffra authorization.

How to Appeal a Kaiser Permanente Denial of Rezdiffra

Denial rates for Rezdiffra are expected to be high at Kaiser given the closed-formulary structure and strict internal pathway. Knowing the appeal process is critical for members who meet clinical criteria but face administrative rejection.

Internal Appeal (Level 1)

Members have 180 days from the date of denial to file an internal appeal through Kaiser member services. The appeal should include:

• A letter of medical necessity from the prescribing Kaiser hepatologist or obesity-medicine specialist
• Liver biopsy results or validated non-invasive fibrosis scores (FibroScan with CAP, ELF, or FIB-4 plus MRI-PDFF)
• Documentation of failed lifestyle interventions with dates, program names, and outcomes
• Documentation of failed or contraindicated alternative pharmacotherapy (pioglitazone, vitamin E, GLP-1 agonists)
• Reference to the MAESTRO-NASH trial data showing statistically significant fibrosis improvement at 52 weeks 2

Kaiser must respond to the internal appeal within 30 calendar days for standard requests or 72 hours for expedited requests involving urgent clinical need.

External Review (State IRO)

If Kaiser denies the internal appeal, members can escalate to their state's independent review organization (IRO). The IRO process varies by state but generally requires filing within 4 months of the internal denial. States like California, where Kaiser has its largest membership base, route these through the California Department of Managed Health Care (DMHC). The DMHC resolved 6,894 independent medical reviews in fiscal year 2023, overturning insurer denials in roughly 60% of cases involving specialty medications, according to DMHC annual report data.

Tips for a Stronger Appeal

Dr. Zobair Younossi, chair of the Global NASH Council, has stated: "Patients with F2-F3 fibrosis and confirmed MASH represent exactly the population where resmetirom showed meaningful histologic benefit. Denying access to these patients requires clinical justification, not just formulary policy." Including such expert-level clinical context in the appeal letter strengthens the case that denial is medically inappropriate.

The American Association for the Study of Liver Diseases (AASLD) practice guidance recommends pharmacotherapy for MASH patients with significant fibrosis (F2 or greater) who do not respond to lifestyle modification 6. Citing this guideline directly in the appeal establishes that Rezdiffra is not experimental but guideline-concordant care.

Can You Use the Manufacturer Savings Card at Kaiser?

Madrigal Pharmaceuticals offers a copay assistance program for commercially insured patients. The practical answer for Kaiser members is: it depends on pharmacy structure.

The Kaiser Pharmacy Limitation

Kaiser's integrated pharmacy model creates a structural barrier. Most manufacturer copay cards are designed for use at retail or specialty pharmacies that process commercial insurance claims through a standard pharmacy benefit manager (PBM). Kaiser acts as its own PBM, and many of its pharmacies do not accept external copay cards. Members should call the Kaiser pharmacy directly and ask whether the Madrigal copay assistance program can be applied at the point of sale.

Alternative Cost Reduction Strategies

If the copay card is not accepted, Kaiser members have several options:

• Madrigal Patient Assistance Program: for members whose income falls below 400% of the federal poverty level, Madrigal may provide Rezdiffra at no cost. Eligibility details are available through the Rezdiffra website or by calling Madrigal's patient support line.
• Out-of-pocket maximum acceleration: members with high-deductible Kaiser plans may benefit from filling Rezdiffra early in the plan year to reach their out-of-pocket maximum faster, reducing costs for the remainder of the year.
• Kaiser financial assistance: Kaiser's own charity care and financial assistance programs may reduce cost-sharing for qualifying members.

Rezdiffra Clinical Profile: What Kaiser Reviewers Evaluate

Understanding the clinical data helps members anticipate what Kaiser's pharmacy and therapeutics committee weighs when reviewing authorization requests.

Efficacy Data from MAESTRO-NASH

The MAESTRO-NASH trial, published in the New England Journal of Medicine in February 2024, randomized 966 adults with biopsy-confirmed MASH and fibrosis stage F1B-F3 to resmetirom 80 mg, 100 mg, or placebo 2. At 52 weeks:

• MASH resolution without fibrosis worsening: 25.9% (80 mg) and 29.9% (100 mg) vs. 9.7% (placebo)
• Fibrosis improvement by at least one stage without NASH worsening: 24.2% (80 mg) and 25.9% (100 mg) vs. 14.2% (placebo)
• LDL cholesterol reduction: approximately 14% from baseline with the 100 mg dose

Both co-primary endpoints achieved statistical significance (P<0.001 for MASH resolution; P<0.01 for fibrosis improvement). Resmetirom is the first drug to demonstrate both histologic endpoints in a phase 3 MASH trial.

Safety Profile

The most common adverse events in MAESTRO-NASH were diarrhea (26.7% vs. 18.2% placebo) and nausea (20.5% vs. 12.8% placebo), both predominantly mild in severity. Serious adverse events occurred at similar rates across treatment and placebo groups. The AASLD guidance notes that resmetirom's thyroid hormone receptor beta selectivity avoids the cardiovascular and bone-density risks associated with non-selective thyroid hormone analogs 6.

Monitoring Requirements

Kaiser physicians will typically require baseline and periodic monitoring of:

• Thyroid function (TSH, free T4) at baseline, 3 months, and every 6 months
• Hepatic panel (ALT, AST, bilirubin, albumin) at baseline and quarterly
• Lipid panel at baseline and 3 months (given the LDL-lowering effect)
• FibroScan or alternative non-invasive fibrosis assessment at 12 months to evaluate treatment response

Kaiser Permanente Regional Variation

Kaiser operates as separate regional entities, and formulary decisions can differ between regions.

Key Regional Differences

Kaiser Permanente Northern California, Southern California, and Mid-Atlantic are the three largest regions. Northern California and Southern California together cover over 8.5 million members. Formulary decisions are made at the regional level by each region's pharmacy and therapeutics committee, which means a drug approved at Kaiser Northwest may not be covered identically at Kaiser Georgia.

How to Confirm Your Region's Policy

Members should take these steps before assuming coverage:

1. Log into kp.org and manage to "Pharmacy" then "Drug Formulary" to search for resmetirom or Rezdiffra
2. Call the member services number on the back of your Kaiser ID card and ask specifically about Rezdiffra prior authorization criteria
3. Request a peer-to-peer review between your Kaiser hepatologist and the plan's pharmacy reviewer if coverage is unclear

Comparing Kaiser Permanente to Other Major Insurers

Kaiser's closed-formulary model places it among the more restrictive insurers for Rezdiffra access. UnitedHealthcare and Aetna, which operate open formularies with specialty-tier placement, allow any in-network prescriber to initiate prior authorization. Blue Cross Blue Shield plans vary by state but generally permit external specialty pharmacy dispensing, making manufacturer copay cards easier to apply.

A 2024 analysis from the Institute for Clinical and Economic Review (ICER) priced resmetirom's value-based benchmark at $20,000 to $34,000 per quality-adjusted life year (QALY), which falls within the commonly cited $50,000-$150,000/QALY willingness-to-pay threshold used by U.S. Payers 7. This cost-effectiveness data may become increasingly relevant as Kaiser regions update their formulary positions.

The Endocrine Society's 2024 clinical practice update emphasizes that "thyroid hormone receptor beta agonists represent a mechanistically distinct approach to MASH that addresses hepatic lipid metabolism directly," positioning resmetirom as a non-redundant therapy rather than a me-too drug 8.